Research map: Oral Targeted Anticancer Medications: Use and Spending by Evidence and Magnitude of Clinical Benefit, 2016-2021

Back to the article

Papers in this map

  1. Patients’ Expectations of the Benefits and Harms of Treatments, Screening, and Tests · Tammy Hoffmann · 2014 · 714 citations · Cited by this paper
  2. Acupuncture in Cancer Care: Evidence, Safety, and Implementation in Oncology Practice · 2026 · Related
  3. FDA Approval and Regulation of Pharmaceuticals, 1983-2018 · Jonathan J. Darrow · 2020 · 381 citations · Cited by this paper
  4. Survival Outcomes in Breast Cancer Patients With Use of Vaginal Estrogen Therapy: A SEER Analysis · 2026 · Related
  5. Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development · Margaret E. Blume‐Kohout · 2012 · 229 citations · Cited by this paper
  6. Turnaround Time of Comprehensive Genomic Profiling in Lung Cancer and Other Solid Tumors · 2026 · Related
  7. Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists · Rena M. Conti · 2013 · 127 citations · Cited by this paper
  8. When Systems Fail the Vulnerable: Cancer Care for Patients With Mental Illness · 2026 · Related
  9. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval · Ian T. T. Liu · 2024 · 127 citations · Cited by this paper
  10. Implementing Systems-Based Interventions to Improve the Care of Cancer Survivors: Small Steps, Large Challenges · 2026 · Related
  11. Trends in Prescription Drug Launch Prices, 2008-2021 · Benjamin N. Rome · 2022 · 110 citations · Cited by this paper
  12. Availability and Use of Social Determinants of Health Data in Alliance Gastrointestinal Cancer Clinical Trials · 2026 · Related
  13. Common Sense Oncology: outcomes that matter · Christopher M. Booth · 2023 · 109 citations · Cited by this paper
  14. Patient Engagement With an Electronic Patient-Reported Outcomes Tool Evaluating Hospital Discharge Readiness After Cancer Surgery · 2026 · Related
  15. Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014 · Stacie B. Dusetzina · 2016 · 107 citations · Cited by this paper
  16. Participation Is Not Reform: Why 340B Discounts Should Follow the Patient · 2026 · Related
  17. Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis · Huseyin Naci · 2024 · 81 citations · Cited by this paper
  18. Dose Optimization and the Implementation of Project Optimus · 2026 · Related
  19. The Patient Experience of Prior Authorization for Cancer Care · Fumiko Ladd Chino · 2023 · 60 citations · Cited by this paper
  20. The US Food and Drug Administration’s expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements · Joshua David Wallach · 2018 · 52 citations · Cited by this paper
  21. Association Between Preapproval Confirmatory Trial Initiation and Conversion to Traditional Approval or Withdrawal in the FDA Accelerated Approval Pathway · Mahnum Shahzad · 2023 · 28 citations · Cited by this paper
  22. Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018 · Mengyuan Fu · 2021 · 27 citations · Cited by this paper
  23. Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval · Mahnum Shahzad · 2021 · 26 citations · Cited by this paper
  24. Physicians’ Perspectives On FDA Regulation Of Drugs And Medical Devices: A National Survey · Sanket Shishir Dhruva · 2024 · 25 citations · Cited by this paper
  25. Evaluation of Trends in Oncology Drug Spending in Medicare, 2016 to 2020 · Michael Anne Kyle · 2022 · 23 citations · Cited by this paper
  26. The FDA Struggle to Withdraw Makena · Daniel Aaron · 2022 · 14 citations · Cited by this paper
  27. Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway · Mahnum Shahzad · 2024 · 9 citations · Cited by this paper
  28. The Complex Cancer Care Coverage Environment — What is the Role of Legislation? · Christine Leopold · 2020 · 8 citations · Cited by this paper
  29. Unintended Consequences of Coverage Laws Targeting Cancer Drugs · Maximilian Salcher‐Konrad · 2020 · 7 citations · Cited by this paper
  30. New Cancer Drug Approvals: Less Than Half Of Important Clinical Trial Uncertainties Reported By The FDA To Clinicians, 2019–22 · Avi Cherla · 2025 · 4 citations · Cited by this paper
  31. Reporting of Clinical Trial Uncertainties With New Cancer Drugs in Journal Publications and Clinical Guidelines · Avi Cherla · 2025 · 4 citations · Cited by this paper
  32. Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit · Lisa S. Rotenstein · 2018 · 3 citations · Cited by this paper
  33. Association between oral targeted cancer drug net health benefit, uptake, and spending · Kelsey S. Lau‐Min · 2024 · 2 citations · Cited by this paper
  34. Financial Toxicity of Withdrawn Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Indications for Ovarian Cancer · Joseph A. Dottino · 2024 · 2 citations · Cited by this paper
  35. Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration’s accelerated approval pathway: retrospective observational study and economic evaluation · Huseyin Naci · 2025 · 1 citation · Cited by this paper
  36. Trends in use of poly (ADP-ribose) polymerase inhibitor (PARPi) in ovarian cancer · Joseph A. Dottino · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)